Medlab Clinical Limited

Equities

MDC

AU000000MDC8

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 15:04:48 2023-02-23 EST			5-day change	1st Jan Change
6.6 ^AUD	-.--%		-5.04%	-.--%

05-15	Medlab Clinical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI
04-24	Medlab Clinical Limited Reports Earnings Results for the Full Year Ended June 30, 2023	CI

Medlab Clinical Limited Receives License from the Victorian State Government to Sell or Supply Schedule 8* or Schedule 9*Drugs

January 09, 2018 at 05:59 pm

Medlab Clinical Limited announced that the company has received the following license from the Victorian State Government: License to Sell or Supply Schedule 8*or Schedule 9*Drugs (limited to cannabis and its derivatives) –NanaBis (cannabis CBD: THC product) and NanaBidial (cannabis CBD Product) will be sold under this license.

Latest news about Medlab Clinical Limited

Medlab Clinical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	05-15	CI
Medlab Clinical Limited Reports Earnings Results for the Full Year Ended June 30, 2023	04-23	CI
Medlab Clinical Limited Announces Change of Share Registry	02-28	CI
Medlab Clinical Limited Reports Earnings Results for the Half Year Ended December 31, 2022	01-08	CI
Australia Inc roiled by string of cyber attacks since late 2022	23-09-29	RE
Australia Inc roiled by raft of cyber attacks since late 2022	23-06-16	RE
Australia Inc roiled by raft of cyberattacks since late 2022	23-03-15	RE
Medlab Clinical Limited Announces Executive Changes	23-03-15	CI
Medlab Clinical Appoints Consultants for Restructure Plan	23-03-06	MT
Medlab Clinical Limited Retrenches 78% of the Workforce	23-03-06	CI
Medlab Clinical Secures Approval to Export Pain Medication to UK	23-02-07	MT
Medlab Clinical Secures UK Import Certificate for Cancer Bone Pain Medication	23-01-25	MT
Medlab Clinical Validates Effectivity of Pain Medication in Real-World Trial	23-01-12	MT
Medlab Announces Interim Readout of Rwe Medcare Study	23-01-11	CI
Medlab Clinical Files Registration Statement for Proposed US IPO	22-12-27	MT
Australia Inc roiled by raft of cyberattacks this year	22-12-13	RE
Medlab Clinical Limited Invoices First Royalty Cheque to PharmaCare	22-11-30	CI
MHRA Approves Medlab Clinical's NanaBis for Use in UK Named Patient Program	22-11-24	MT
Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis	22-11-24	CI
Medlab Clinical's Nasal RNA Program in Final Development Stages	22-11-10	MT
Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update	22-11-09	CI
Factbox-Australia Inc roiled by raft of cyberattacks this year	22-11-06	RE
Australia pathology data stolen as hacking epidemic widens	22-10-26	RE
Medlab Clinical Limited Auditor Raises 'Going Concern' Doubt	22-10-12	CI
Medlab Clinical Set for Nasdaq Listing	22-09-28	MT

Chart Medlab Clinical Limited

Duration

Period

More charts

Company Profile

Medlab Clinical Limited (Medlab) is an Australia-based biotechnology company focused on the development and commercialization of a pharmaceutical delivery platform. The Company is investigating a range of prescription and non-prescription solutions for unmet patient needs across a variety of therapeutic areas, including pain management, mental health, gut health, diabetes, and allergies. The Companyâs drug candidates include NanaBis, NanoCBD and NanoCelle. Medlabâs pipeline comprises a range of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The Company's lead drug candidate, NanaBis, is under development for cancer bone pain as an alternative to opioid use and NanoCBD for mental stress . The Company also has a drug delivery platform called NanoCelle, which is wholly owned by Medlab and developed in Medlabâs owned Office of the Gene Technology Regulator (OGTR) registered laboratory.

Sector

Biotechnology & Medical Research

Calendar

2024-08-29 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEDLAB CLINICAL LIMITED	-.--%	10.01M
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B
INSMED INCORPORATED	+77.64%	8.87B

Bio Therapeutic Drugs